Web Analytics

3 Latest Announced Rounds

  • $90,000,000
    Series A

    2 Investors

    Software Development
    Oct 7th, 2025
  • $1,311,818
    Pre-Seed

    1 Investors

    Renewable Energy Semiconductor Manufacturing
    Oct 7th, 2025
  • $97,716,710
    Series A

    2 Investors

    Biotechnology
    Oct 7th, 2025
$1,088.68M Raised in 44 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Phialogics - The immune tolerance company

start up
Germany - Frankfurt, Hesse
  • 08/05/2023
  • Pre-Seed
  • $662,970

Our immune checkpoint activators protect patient’s organ tissue.
Unique approach :
- Potential for BEST-in-class super agonist against immune-mediated tissue damage
- High selectivity for active T-cells
- Proof of concept in relevant human in vitro models and mouse model of disease


Related People

Andreas ErnstFounder

Andreas Ernst Germany - ND

Expert in protein engineering with a keen interest in drug development for the treatment of autoimmune diseases.